Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).
| Excerpt | Reference |
|---|
| "In p." | ( Descos, L; Gagnaire, JC; Magnin, P, 1975) |
| "The experimental cholestasis is accompanied by accumulation of hydroxylated derivatives of cholesterol, which possess the detergent characteristics and destruct the substrate binding sites in P-450 molecule." | ( Liakhovich, VV; Mordvinov, VA; Tsyrlov, IB; Zakharova, NE, 1976) |
| "Cholestasis is a rare manifestation of methyldopa hepatotoxicity." | ( Amir, G; Moses, A; Zahger, D, 1989) |
| "The cause of the cholestasis is probably related to subcellular organelle damage produced by cold ischemia, and its importance stems from the confusion it creates with regard to rejection diagnosis." | ( Britt, LG; Dean, PJ; Haggitt, R; Massie, JD; Peters, TG; Van Voorst, S; Vera, S; Williams, JW, 1986) |
| "TLC-induced cholestasis is associated more closely with bile canalicular membrane changes than with extent of hepatocellular necrosis." | ( Baumgartner, U; Hardison, WG; Miyai, K, 1987) |
| "Since cholestasis is a common, although poorly recognized, complication of chronic pancreatitis, and bile acids seem to be a sensitive index of cholestasis, fasting and post-prandial s-cholic and s-chenodeoxycholic acids were determined by radioimmunoassay in 48 chronic alcoholic pancreatitis patients (CP) and 22 healthy controls (C)." | ( Angelini, G; Antolini, G; Cavallini, G; Franchini, CA; Fratton, S; Micciolo, R; Scuro, LA; Tonon, M; Vaona, B, 1983) |
| "Since EE-induced cholestasis is related to the condition observed in humans, a clinical trial of DHBE in cholestatic syndromes seems worthwhile." | ( Di Padova, C; Dioguardi, ML; Festorazzi, S; Podda, M; Zuin, M, 1980) |
| "Cholestasis is associated with a marked increase in the release of canalicular membrane enzymes into bile." | ( Accatino, L; Arrese, M; Koenig, C; Pizarro, M; Solís, N, 1995) |
| "Cholestasis is a biochemical and/or histological feature observed in some patients with alcoholic liver disease and is mainly related to alcoholic hepatitis." | ( Balkau, B; Gerhardt, MF; Munz, C; Poupon, RE; Trinchet, JC, 1994) |
| "Cholestasis is the predominant complication in patients with total parenteral nutrition-related liver disease." | ( Beau, P; Beauchant, M; Ingrand, P; Labat-Labourdette, J, 1994) |
| "Cholestasis is one of the most frequent complications of Total Parenteral Nutrition (TPN)." | ( Belli, DC; Bugmann, P; La Scala, GC; Le Coultre, C; Roche, BG, 1993) |
| "Cholestasis is a frequent problem in patients on total parenteral nutrition (TPN) therapy." | ( Dinari, G; Hackelman, B; Marcus, H; Nussinovitch, M; Zahavi, I, 1996) |
| "Pure hepatocellular cholestasis is mostly observed with sex steroid hormones and anabolic steroids." | ( Erlinger, S, 1997) |
| "Cholestasis is an infrequent adverse effect of this drug." | ( Avagnina, A; Díaz Fuenzalida, A; Findor, JA; Laudano, O; Valdés Socín, H, 1997) |
| "Cholestasis is a cardinal complication of liver disease, but most treatments are merely supportive." | ( Burgstahler, AD; Dranoff, JA; Mennone, A; Nathanson, MH; Rios-Velez, L, 1998) |
| "Cholestasis is common in infants with neonatal intestinal resection." | ( Asturias, E; Cadnapaphornchai, M; Sondheimer, JM, 1998) |
| "Cholestasis is one of the major complications of parenteral nutrition." | ( Atik, E; Demircan, M; Gurer, EI; Gursoy, MH; Mutus, M; Turhan, F; Uguralp, S, 1999) |
| "Cholestasis is a frequent problem in patients on total parenteral nutrition." | ( Dinari, G; Heckelman, B; Marcus, H; Rosezki, O; Shamir, R; Stolkarts, Y; Zahavi, I, 2000) |
| "Obstetric cholestasis is a liver disease of pregnancy that can be complicated by sudden, hitherto unexplained, intra-uterine fetal death." | ( de Swiet, M; Eaton, BM; Gorelik, J; Korchev, Y; Lab, M; Williamson, C, 2001) |
| "Cholestasis is associated with the overproduction of nitric oxide (NO), and NO acts as an inhibitory mechanism when thirst is stimulated by water deprivation or by angiotensin II." | ( Dehpour, AR; Mani, AH; Mani, AR; Nahavandi, A, 2001) |
| "Cholestasis is also associated with accumulation of endogenous opioid peptides and evidence of overproduction of nitric oxide (NO)." | ( Dehpour, AR; Gaskari, SA; Homayoun, H; Mehr, SE; Namiranian, K; Rastegar, H; Samini, M, 2001) |
| "Cholestasis is associated with NO overproduction." | ( Akbari, MR; Dehpour, AR; Homayounfar, H; Mani, AR; Nahavandi, A, 2001) |
| "Cholestasis is associated with elevated plasma level of endogenous opioid peptides." | ( Arad, MA; Dehpour, AR; Namiranian, K; Samini, M, 2001) |
| "Cholestasis is associated with retention of potentially toxic bile acids and profound cytoskeletal alterations of hepatocytes." | ( Denk, H; Fickert, P; Fuchsbichler, A; Stumptner, C; Trauner, M; Zatloukal, K, 2002) |
| "Acute cholestasis is associated with increased activity of the endogenous opioid system." | ( Afifi, M; Dehpour, AR; Homayoun, H; Rastegar, H; Rezayat, M, 2002) |
| "Bilirubin-induced cholestasis is due to markedly impaired activity of the membrane-embedded bsep transporter consequent upon ultrastructural injury to the canalicular membrane." | ( Arnkvaern, K; Bjørnbeth, BA; Labori, KJ; Press, CM; Raeder, MG, 2002) |
| "Obstetric cholestasis is characterized by raised bile acids, and can be complicated by intrauterine death." | ( de Swiet, M; Gorelik, J; Harding, SE; Koralage, D; Korchev, Y; Lab, M; Shevchuk, AI; Williamson, C, 2002) |
| "Chronic cholestasis is associated with retention of bile acids and profound cytoskeletal alterations in hepatocytes including Mallory body (MB) formation." | ( Denk, H; Fickert, P; Fuchsbichler, A; Stumptner, C; Trauner, M; Zatloukal, K, 2002) |
| "Estrogen-mediated cholestasis is an important clinical entity, but its molecular pathophysiology is still not fully understood." | ( Dietrich, CG; Gartung, C; Geier, A; Gerloff, T; Haendly, J; Kullak-Ublick, GA; Matern, S; Meier, PJ; Stieger, B, 2003) |
| "Cholestasis is also associated with accumulation of endogenous opioid peptides and nitric oxide (NO) overproduction." | ( Dehghani, M; Dehpour, AR; Sadeghipour, H, 2003) |
| "We concluded that cholestasis is associated with the decreased responsiveness of alpha(2)-adrenoceptors and the cholestasis-associated augmented opioidergic tone and increased NO production contribute to this process." | ( Dehpour, AR; Demehri, S; Gaskari, SA; Mehr, SE; Namiranian, K; Rastegar, H; Roushanzamir, F; Shariftabrizi, A, 2003) |
| "Intrahepatic cholestasis is often associated with impairment of biliary bile acid secretion, a process mediated by the sister of P-glycoprotein (Spgp or Abcb11) also known as the bile salt export pump (Bsep)." | ( Forrest, D; Lam, P; Ling, V; Liu, L; Mignault, D; Phillips, MJ; Wang, R; Yousef, IM, 2003) |
| "Early cholestasis is not uncommon after liver transplantation and usually signifies graft dysfunction." | ( Bar-Nathan, N; Ben-Ari, Z; Brown, M; Mor, E; Shaharabani, E; Shapira, Z; Sulkes, J; Tur-Kaspa, R; Weiss-Schmilovitz, H; Yussim, A, 2004) |
| "Obstetric cholestasis is associated with intrauterine death." | ( de Swiet, M; Gorelik, J; Korchev, Y; Lab, M; Shevchuk, A; Williamson, C, 2004) |
| "Cholestasis is associated with accumulation of bile acids and lipids, and liver injury." | ( Alvarez, JG; Coulter, SA; Downes, M; Evans, RM; Liddle, C; Moore, DD; Sonoda, J; Stedman, CA, 2005) |
| "Cholestasis is associated with vascular changes and in previous studies decreased response of visceral vessels of cholestatic animals to phenylephrine and acetylcholine has been shown." | ( Borhani, AA; Dehpour, AR; Ebrahimi, F; Hajrasouliha, AR; Houshmand, G; Namiranian, K; Samini, M; Tavakoli, S, 2005) |
| "Cholestasis is associated with naloxone reversible antinociception and opiate receptor antagonists are used clinically to treat pruritus." | ( Chapman, K; D'Mello, C; Le, T; Nelson, L; Swain, MG; Vergnolle, N, 2006) |
| "Cholestasis is associated with high morbidity and mortality in patients undergoing major liver surgery, but the mechanisms responsible remain elusive." | ( Clavien, PA; Dahm, F; Eloranta, JJ; Georgiev, P; Graf, R; Jochum, W; Kullak-Ublick, GA; Lang, KS; Navarini, AA; Nocito, A, 2007) |
| "Cholestasis is a common complication in patients with extrahepatic bacterial infection and sepsis." | ( Fickert, P; Geier, A; Trauner, M, 2006) |
| "Acute cholestasis is associated with increased activity of the endogenous opioid system that results to changes including analgesia." | ( Allahtavakoli, M; Ghaseminejad, M; Hasanein, P; Javanmardi, K; Keshavarz, M; Parviz, M, 2007) |
| "Cholestasis is a major complication in sepsis although the underlying mechanisms remain elusive." | ( Jeppsson, B; Laschke, MW; Lindell, G; Menger, MD; Thorlacius, H; Wang, Y, 2007) |
| "Cholestasis is associated with changes in NO metabolism and thiol oxidation." | ( Grattagliano, I; Palasciano, G; Palmieri, VO; Portincasa, P, 2007) |
| "Cholestasis is characterized by hypercholesterolemia and the appearance of an abnormal lipoprotein, lipoprotein X (LpX), in plasma." | ( Amigo, L; Bravo, I; Cohen, DE; Francone, O; Nervi, F; Rigotti, A; Zanlungo, S, 2007) |
| "Maternal cholestasis is usually a benign condition for the mother but induces profound placental damage and may be lethal for the fetus." | ( Castaño, B; Gonzalez-Buitrago, JM; Marin, JJ; Perez, MJ, 2007) |
| "Cholestasis is associated with increased activity of the endogenous opioid system that results in analgesia." | ( Hasanein, P; Komaki, A; Mirazi, N; Shahidi, S, 2008) |
| "Neonatal cholestasis is rare but serious problem that indicates hepatobiliary dysfunction and has several categories of etiologies." | ( Dahshan, A, 2009) |
| "Cholestasis is associated with increased activity of the endogenous opioid system that results in analgesia." | ( Hasanein, P, 2009) |
| "Cholestasis is associated with analgesia." | ( Hasanein, P, 2011) |
| "Cholestasis is associated with a moderation of the degree of hypocholesterolemia." | ( Ardito, F; Chiarla, C; Clemente, G; Giovannini, I; Giuliante, F; Murazio, M; Nuzzo, G; Vellone, M; Zadak, Z, 2010) |
| "Cholestasis is a serious complication of many liver diseases leading to increased serum bile acids (BA) and their conjugates." | ( Aehlen, A; Ehmer, U; Erichsen, TJ; Kalthoff, S; Manns, MP; Strassburg, CP, 2010) |
| "Cholestasis is a reduction in bile flow that occurs from a variety of causes in humans." | ( Copple, BL; Jaeschke, H; Klaassen, CD, 2010) |
| "Acute cholestasis is associated with cardiovascular complications." | ( Dehpour, AR; Doostar, Y; Ebrahimi, F; Ghasemi, M; Hashemi, M; Moezi, L; Shafaroodi, H, 2010) |
| "Cholestasis is associated with changes including analgesia." | ( Hasanein, P, 2010) |
| "Severe cholestasis is one of the important causes of prolonged hospitalization in patients with acute hepatitis A." | ( Choi, JH; Jung, SW; Kim, JH; Kim, SY; Lee, HJ; Lee, JH; Lee, SW; Lee, YS; Yim, HJ; Yoon, EL, 2010) |
| "Cholestasis is a significant risk factor for immediate hepatic failure due to ischemia reperfusion (I/R) injury in patients undergoing liver surgery or transplantation." | ( Eason, JD; Lakshmi, R; Mahato, RI; Modanlou, KA; Panakanti, R; Pratap, A; Yang, N, 2011) |
| "Cholestasis is associated with endotoxinemia and elevated serum levels of bile acids, cholesterol, bile salts and opioids." | ( Eslimi, D; Nasehi, M; Oryan, S; Zarrindast, MR, 2011) |
| "Severe cholestasis is a rare presenting feature of Graves' disease." | ( Arnon, R; Kerkar, N; Miloh, T; Morotti, R; Rapaport, R; Regelmann, MO, 2012) |
| "Neonatal cholestasis is associated with increased mortality and other adverse outcomes." | ( Abbasi, S; DeMauro, SB; Gerdes, JS; Kilpatrick, LE, 2012) |
| "Sepsis-induced cholestasis is a complication of infection." | ( Bhogal, HK; Sanyal, AJ, 2013) |
| "Obstructive cholestasis is associated with overproduction of endogenous opioids, nitric oxide (NO) and cytokines in the blood stream." | ( Monsef, A, 2012) |
| "Cholestasis is a condition in which there is a decrease in or complete cessation of bile flow." | ( Hendaus, M, 2013) |
| "Cholestasis is associated with changes in hepatic cholesterol metabolism and serum estrogen levels." | ( Kobayashi, H; Naito, A; Shirasawa, N; Sun, YJ; Yoshida, S, 2013) |
| "Cholestasis is a significant life-threatening complication in children on parenteral nutrition (PN)." | ( Aufieri, R; Cananzi, M; Chiesa, PL; Eaton, S; Lauriti, G; Pierro, A; Zani, A, 2014) |
| "Cholestasis is a pathological common component of numerous liver diseases that results in hepatotoxicity, inflammation, and cirrhosis when untreated." | ( Antoine, DJ; Bajt, ML; Jaeschke, H; Jenkins, RE; Park, BK; Woolbright, BL, 2013) |
| "Hepatic cholestasis is a pathophysiological feature observed in all stages of ALD." | ( Gu, J; Jia, D; Peng, X; Wu, W; Zhou, M; Zhu, B, 2014) |
| "Cholestasis is rare in children with only a few cases reported but it was described in up to 55% of the adult population affected." | ( Cunha, F; Salva, I; Silva, IV, 2013) |
| "Cholestasis is an uncommon condition in CF affecting only 5." | ( Cipolli, M; Fitzgerald, DA; Gaskin, KJ; Leeuwen, L; Magoffin, AK, 2014) |
| "Cholestasis is characterized by the elevation of serum total bile acids (TBA), which leads to the production of both free radicals and oxidative stress." | ( Kučerová, V; Leníček, M; Muchová, L; Petr, T; Smíd, F; Smíd, V; Váňová, K; Vítek, L, 2014) |
| "Neonatal cholestasis is an important cause of chronic liver disease in young children." | ( Bavdekar, A; Bhatia, V; Matthai, J; Sibal, A; Waikar, Y, 2014) |
| "Estrogen-induced cholestasis is characterized by impaired hepatic uptake and biliary bile acids secretion because of changes in hepatocyte transporter expression." | ( Cerny, D; Dolezelova, E; Farghali, H; Fuksa, L; Lenicek, M; Micuda, S; Muchova, L; Suk, J; Vanova, K; Vitek, L; Vreman, HJ; Wong, RJ; Zelenkova, M, 2015) |
| "Neonatal cholestasis is a common cause of jaundice among newborns." | ( Ali, SW; Hassan, MU; Khan, SH; Malik, D; Pakala, R; Pasupula, M; Rather, TA; Yadav, N, 2015) |
| "Obstructive cholestasis is characterized by impairment of hepatic canalicular bile efflux and there are no clinically effective drugs to cure except surgeries." | ( Bi, H; Chen, P; Deng, R; Fan, X; Huang, M; Li, D; Li, J; Zeng, H, 2015) |
| "In particular, cholestasis is difficult to diagnose by conventional markers at an early stage of disease." | ( Amano, K; Masubuchi, N; Matsuura, T; Nakano, M; Sugihara, M; Sugita, T, 2016) |
| "Markers of cholestasis are associated with adverse outcome." | ( Jenniskens, M; Langouche, L; Mesotten, D; Van den Berghe, G; Vanwijngaerden, YM, 2016) |
| "Cholestasis is a leading cause of hepatic accumulation of bile acids resulting in liver injury, fibrosis, and liver failure." | ( Chen, H; Chen, Z; Li, J; Liu, L; Ma, X; Niu, M; Su, H; Wang, J; Wang, R; Wei, Z; Xiao, X; Zhao, Q; Zhao, Y; Zhu, Y, 2016) |
| "Cholestasis is a frequent symptom at presentation of PSIS during the neonatal period that may help earlier diagnosis and that indicates a profound cortisol deficiency." | ( Brauner, R; Davit-Spraul, A; Gonzales, E; Jacquemin, E; Mauvais, FX, 2016) |
| "Cholestasis is characterized by accumulation of bile acids and inflammation, causing hepatocellular damage." | ( Buist-Homan, M; Faber, KN; Groen, AK; Koehorst, M; Moshage, H; Verhaag, EM, 2016) |
| "Cholestasis is a clinically significant symptom and widely associated with liver diseases, however, there are very few effective therapies for cholestasis." | ( Ding, L; Gong, J; Tang, X; Wang, G; Wang, Z; Yang, F; Yang, L; Yang, Q; Zhou, Y, 2016) |
| "Cholestasis is a major systemic disorder associated with distressing pruritus (itch)." | ( Azimi, E; Dehpour, AR; Foroutan, A; Kordjazy, N; Momeny, M; Norouzi-Javidan, A; Ostadhadi, S, 2016) |
| "Cholestasis is a common complication of sepsis, and the increased plasma levels of bile acids are predictive of sepsis-associated mortality." | ( Cao, L; Che, Y; Gonzalez, FJ; Hao, H; Jiang, C; Takahashi, S; Wang, G; Zhang, S, 2017) |
| "Cholestasis is a presenting feature of BA, as well as other diagnoses (Non-BA)." | ( Arnon, R; Bezerra, JA; Guthery, SL; Kamath, BM; Karpen, SJ; Kerkar, N; Loomes, KM; Magee, JC; Molleston, JP; Moore, J; Murray, KF; Rosenthal, P; Schwarz, KB; Sherker, AH; Shneider, BL; Sokol, RJ; Squires, RH; Turmelle, YP; Whitington, PF; Ye, W, 2017) |
| "Cholestasis is a clinical disorder defined as an impairment of bile flow, and that leads to toxic bile acid (BA) accumulation in hepatocytes." | ( Hu, P; Hu, Y; Huang, F; Jia, W; Liang, C; Liu, P; Wang, X; Xie, G; Yan, J; Zhao, A, 2017) |
| "Cholestasis is one of the major causes of drug-induced liver injury (DILI), which can result in withdrawal of approved drugs from the market." | ( Honda, H; Ito, Y; Kawamoto, T; Morita, O, 2017) |
| "Cholestasis is the stoppage of bile flow which could lead to serious clinical complications if not managed." | ( Abdoli, N; Aghaei, F; Ahmadi, A; Azarpira, N; Esfandiari, A; Ghanbarinejad, V; Heidari, R; Mohammadi, H; Niknahad, H; Ommati, MM, 2018) |
| "Cholestasis is defined as a functional impairment of bile secretion which results in the accumulation of bile acids (BAs) and other toxic molecules in the blood and liver, however, there are very few effective therapies for cholestasis." | ( Ding, L; Li, J; Wang, Z; Yang, L; Zhang, B, 2018) |
| "Cholestasis is a disorder characterized by impaired bile flow and accumulation of cytotoxic bile acids in the liver." | ( Ahmadi, A; Azarpira, N; Esfandiari, A; Ghanbarinejad, V; Heidari, R; Mohammadi, H; Niknahad, H, 2018) |
| "The pruritus of cholestasis is a maddening complication of liver disease." | ( Bergasa, NV, 2018) |
| "Cholestasis is a common complication in infants receiving prolonged parenteral nutrition (PN)." | ( Alves, M; Cordeiro-Ferreira, G; Koletzko, B; Nóbrega, S; Papoila, AL; Pereira-da-Silva, L; Pita, A; Rosa, ML; Serelha, M; Virella, D, 2017) |
| "Cholestasis is a clinical syndrome with systemic and intrahepatic accumulation of excessive toxic bile acids that ultimately cause hepatobiliary injury." | ( Fu, T; Gao, X; Huo, X; Liu, K; Liu, Z; Ma, X; Meng, Q; Ning, C; Sun, H; Wang, C; Yang, X; Zou, M, 2018) |
| "Cholestasis is characterized by the obstruction of bile duct, including primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC)." | ( Hu, DD; Huang, JF; Li, F; Xiao, XR; Yang, R; Zhao, Q, 2018) |
| "Cholestasis is a serious complication of total parenteral nutrition (TPN) in neonates." | ( Ares, GJ; Buonpane, CL; Cohran, VC; Englert, EG; Helenowski, I; Hunter, CJ, 2018) |
| "Cholestasis is a common feature of liver injury, which manifests as bile acid excretion and/or enterohepatic circulation disorders." | ( Cui, SC; Gong, LK; Lu, HL; Ren, J; Wang, L; Wu, SY; Xing, GZ; Yan, XX; Zhang, YT, 2018) |
| "Cholestasis is the major cause of the accumulation of bile acids and results in liver damage, fibrosis, and failure." | ( Han, H; Wang, Z; Xiong, K; Xu, L; Zhang, T, 2018) |
| "Cholestasis is a critical risk factor for severe hepatic disease or cirrhosis." | ( Gao, SJ; He, X; Li, PY; Ma, X; Wei, SZ; Wen, JX; Xiao, XH; Yang, YX; Zhao, YL, 2018) |
| "Cholestasis is a condition wherein bile flow is interrupted and lithocholic acid is known to play a key role in causing severe liver injury." | ( Aini, W; Miyagawa-Hayashino, A; Ozeki, M; Tamaki, K, 2019) |
| "Cholestasis is one of the most challenging diseases to be treated in current hepatology." | ( Chang, L; Dai, M; Hu, X; Hua, H; Lin, H; Liu, A; Luo, Y; Tang, Z; Xu, G; Xu, L; Yang, J; Zhang, H, 2019) |
| "Cholestasis is defined as a reduction of bile secretion caused by a dysfunction of bile formation." | ( Inoue, A; Kishi, K; Koh, M; Miyazaki, H; Takitani, K; Tamai, H; Tamaki, H, 2018) |
| "Cholestasis is characterized by intrahepatic accumulation of cytotoxic bile acids (BAs), ultimately leading to fibrosis and cirrhosis, but the precise role of BAs in cholestasis-induced liver fibrosis remains largely elusive." | ( Chen, XP; Ding, ZY; Jin, GN; Liang, HF; Ma, M; Yu, B; Zhang, BX, 2018) |
| "Cholestasis is a devastating liver condition which is increasing in prevalence worldwide; however, its underlying pathogenic mechanisms remain to be fully elucidated." | ( Deng, H; Deng, X; Li, Y; Shi, S; Shi, X; Wang, D; Wang, Y; Xu, Z; Yu, H; Zeng, B; Zhong, X, 2019) |
| "Neonatal cholestasis is a group of rare disorders of impaired bile flow characterized by conjugated hyperbilirubinaemia in the newborn and young infant." | ( Feldman, AG; Sokol, RJ, 2019) |
| "Sepsis-related cholestasis is a diagnosis of exclusion that should be considered in case of jaundice in critically ill patients." | ( Borys, M; Czczuwar, M; Kutnik, P; Piwowarczyk, P; Potręć-Studzińska, B; Rypulak, E; Sysiak-Sławecka, J, 2019) |
| "Liver cholestasis is characterized by impairment in bile flow." | ( Coll, M; Pose, E; Sancho-Bru, P, 2019) |
| "Cholestasis is common after burn injuries and is associated with burn severity, sepsis, organ failure and mortality." | ( Benyamina, M; Chaouat, M; Chaussard, M; Coutrot, M; Cupaciu, A; De Kerviler, E; de Tymowski, C; Dépret, F; Ferry, A; Fratani, A; Jully, M; Legrand, M; Mallet, V; Mebazaa, A; Mimoun, M; Moreau, R; Nabila, M; Oueslati, H; Sogni, P; Soussi, S; Vauchel, T; Zagdanski, AM, 2019) |
| "Estrogen-induced cholestasis is associated with the accumulation of endogenous bile acids, which play critical roles in the disease progression and symptoms." | ( Dong, R; Fu, T; Huo, X; Liu, K; Ma, X; Meng, Q; Sun, H; Wang, C; Wang, J; Yang, X, 2019) |
| "Estrogen-induced cholestasis is a common etiology of hepatic diseases in women with contraceptives administration, pregnancy or hormone replacement therapy." | ( Dong, R; Gao, X; Liu, K; Liu, Z; Ma, X; Meng, Q; Sun, H; Wang, C; Wang, J; Wu, J, 2019) |
| "Cholestasis is a liver disease associated with retention of bile in the liver, which leads to local hepatic inflammation and severe liver damage." | ( Beirnaert, C; Covaci, A; Cuykx, M; Laukens, K; Rodrigues, RM; Vanhaecke, T, 2019) |
| "Cholestasis is a clinical syndrome caused by toxic bile acid retention that will lead to serious liver diseases." | ( Bi, H; Chen, Y; Fan, S; Fu, K; Gao, Y; Huang, M; Jiang, Y; Liu, C; Yao, X, 2019) |
| "Cholestasis is a DILI that results from impairment of bile acid transporters, such as the bile salt export pump (BSEP), leading to accumulation of bile acids." | ( Fujino, C; Ishida, Y; Kisoh, K; Kotake, Y; Ohta, S; Sanoh, S; Sugahara, G; Tamura, Y; Tateno, C; Yanagi, A; Yoshizane, Y, 2019) |
| "Liver cholestasis is a complex disease of broad etiologies." | ( Abdel-Rahman, N; El-Awady, MS; Megahed, N; Sharawy, MH, 2019) |
| "Cholestasis is problematic for infants with intestinal failure (IF)." | ( Berris, K; Bhiladvala, C; Casson, C; Channabasappa, N; Dasgupta, T; Nayak, P; Nguyen, V; Panczuk, J; Piper, HG, 2020) |
| "Cholestasis is a condition in which the bile duct becomes narrowed or clogged by a variety of factors and bile acid is not released smoothly." | ( Cho, DH; Han, JH; Kim, S; Lee, CH; Lee, H; Nam, DH; Woo, CH, 2020) |
| "Prolonged cholestasis is a rare complication associated with endoscopic retrograde cholangiopancreatography (ERCP)." | ( Huang, WC; Lin, CK, 2020) |
| "Cholestasis is caused by the obstacle of bile formation or secretion and can develop into severe liver diseases." | ( Bi, HC; Chen, YX; Fu, KL; Guan, LH; Huang, M; Huang, QF; Li, DS; Li, X; Wan, JB; Zhang, HZ, 2020) |
| "Cholestasis is a pathophysiological process caused by the damage of hepatocytes or obstruction of bile flow, which often leads to emotional disorder in central nervous system." | ( Huang, F; Shi, H; Tao, Y; Wu, H; Wu, X; Zhou, J; Zhu, H, 2020) |
| "Cholestasis is a rare distinct complication of hepatitis A infection." | ( Goyal, JP; Jayappa, M; Kumar, P, 2020) |
| "Cholestasis is more common in patients with diarrhea and vice versa." | ( Kiss, O; Maizik, J; Orav, A; Reintam Blaser, A; Tamme, K; van de Poll, MCG, 2020) |
| "Cholestasis is defined as hepatocyte and cholangiocyte bile excretion failure or failure of bile transport to the duodenum." | ( Fejfar, T; Hůlek, P; Vaňásek, T, 2020) |
| "Chronic cholestasis is a usual clinical pathological process in hepatopathy and has few treatment options; it is classified under the category of jaundice in Chinese medicine." | ( Fang, S; Li, H; Li, Y; Ma, Y; Shi, R; Wang, T; Wu, J; Xue, H; Zhang, M; Zheng, M, 2021) |
| "Cholestasis is characterized by obstruction of bile flow and can lead to serious liver injury." | ( Fang, S; Li, Y; Ma, Y; Shi, R; Wang, G; Wang, T; Wang, Y; Wu, J; Xue, H, 2021) |
| "Cholestasis is one of the most severe manifestations of liver injury and has limited therapeutic options." | ( Fan, Y; Li, G; Liu, J; Xu, T; Yu, H; Zhang, C; Zhang, Y; Zhou, L, 2021) |
| "Cholestasis is a bile flow reduction that induces apoptosis, oxidative stress, and inflammation, and alters the expression of genes." | ( Eteghadi, MR; Hesami-Tackallou, S; Nasehi, M; Vaseghi, S, 2021) |
| "Cholestasis is a complex hepatic disorder underlined with retention of the highly toxic bile components within the hepatocytes." | ( Helal, MG; Nazmy, EA; Said, E, 2021) |
| "Infants with cholestasis are at risk of fat-soluble vitamin deficiency." | ( Dhawan, A; Islam, M; Mancell, S; Whelan, K, 2022) |
| "Cholestasis is often associated with SPF-induced hepatotoxicity." | ( Hua, Z; Jiang, Z; Li, W; Liu, H; Mei, C; Min, L; Wu, Y; Xu, Y; Zhou, N, 2022) |
| "Post-ALF cholestasis is ubiquitous." | ( Bellomo, R; Gow, P; Holmes, N; Kishore, K; Marhoon, N; Michel, C; Serpa Neto, A; Sinclair, M; Testro, A; Warming, S; Warrillow, S, 2022) |
| "Cholestasis is a clinical syndrome with high incidence and few effective treatments." | ( Huang, C; Liu, F; Liu, J; Meng, C; Xia, C, 2022) |
| "Cholestasis is a common liver injury without any effective therapeutic drugs so far." | ( Li, K; Ran, X; Wang, W; Wei, X; Wu, W; Xu, X; Zhang, T; Zhang, Y, 2022) |
| "Cholestasis is characterized by an intrahepatic accumulation of BAs and subsequent spillage to the systemic circulation." | ( Bouwmeester, H; de Bruijn, VMP; Rietjens, IMCM, 2022) |
| "Cholestasis is the accumulation of bile acids in the liver due to impaired bile formation, secretion, and excretion caused by infections, drugs, metabolic or genetic diseases." | ( Kang, P; Li, S, 2022) |
| "Cholestasis is characterized by intrahepatic accumulation of bile acids (BAs), resulting in liver injury, fibrosis, and liver failure." | ( Chai, J; Fu, L; Peng, S; Tao, L; Wang, H; Zhang, J; Zhang, X; Zhao, N; Zhou, Z, 2022) |
| "Cholestasis is characterized by bile acid (BA) circulation disorders, which is usually related to damage of hepatocyte barrier function." | ( Jiang, S; Liang, Y; Tang, L; Wang, W; Xu, C; Zhao, Y; Zhu, G, 2022) |
| "Cholestasis is characterized by bile acid (BA) circulation disorders, which is usually related to damage of hepatocyte barrier function." | ( Jiang, S; Liang, Y; Tang, L; Wang, W; Xu, C; Zhao, Y; Zhu, G, 2022) |
| "Cholestasis is characterized by bile acid (BA) circulation disorders, which is usually related to damage of hepatocyte barrier function." | ( Jiang, S; Liang, Y; Tang, L; Wang, W; Xu, C; Zhao, Y; Zhu, G, 2022) |
| "Cholestasis is characterized by impaired bile flow which results in inflammation, cirrhosis, and ultimately liver failure." | ( Attar, R; Khalil, A; Malkani, N; Mumtaz, S; Sohail, I; Tahir, N, 2022) |
| "Cholestasis is characterized by impaired bile flow which results in inflammation, cirrhosis, and ultimately liver failure." | ( Attar, R; Khalil, A; Malkani, N; Mumtaz, S; Sohail, I; Tahir, N, 2022) |
| "Acute cholestasis is one of the most common forms of hepatotoxicity induced by azathioprine." | ( Battezzati, PM; Cataletti, G; Pastorelli, L; Santagata, F, 2022) |
| "Cholestasis is primarily caused by bile acid homeostasis dysregulation, resulting in retention, aggregation, and accumulation of the toxic cholate in the hepatocytes." | ( Ahmed A Saad, A; Baldi, S; Refat, M; Wu, X; Zhang, G; Zheng, F, 2023) |
| "Intrahepatic cholestasis is a common pathological condition of several types of liver disorders." | ( Ali, FEM; Fathy, M; Fawzy, MA; Nasr, G, 2023) |
| "Cholestasis is a clinical complication that primarily influences the liver." | ( Abdoli, N; Ahmadi, P; Alidaee, S; Arjmand, A; Azarpira, N; Ghiasvand, A; Heidari, R; Khodaei, F; Mazloomi, S; Najibi, A; Niknahad, H; Nikoozadeh, A; Ommati, MM; Rezaei, H; Sabouri, S, 2023) |
| "Cholestasis is a pathophysiologic syndrome with limited therapeutic options." | ( Hu, Y; Huang, K; Jin, J; Li, Y; Liu, C; Qiu, F; Song, G; Sun, X; Weng, F; Yan, D; Zhao, J; Zou, B, 2023) |
| "Cholestasis is challenging to treat due to lacked effective drugs." | ( Du, M; Li, Y; Liu, H; Song, X; Tian, C; Zhang, G, 2023) |
| "Cholestasis is a pathophysiological syndrome characterized by the accumulation of bile acids (BAs) that leads to severe liver disease." | ( Jin, J; Li, Y; Liu, C; Qiu, F; Song, G; Sun, X; Weng, F; Xu, X; Yan, D; Zhang, S; Zhao, J; Zou, B, 2023) |
| "Cholestasis is a health problem, both in humans and animals, which in the disease's course involves oxidative stress, inflammation, and liver fibrosis." | ( Lukiswanto, BS; Widyawati, R; Yuniarti, WM, 2023) |
| "Cholestasis is the stoppage of bile flow, leading to the accumulation of potentially cytotoxic bile components in the liver." | ( Ahmadi, P; Alidaee, S; Arjmand, A; Azarpira, N; Ghiasvand, A; Heidari, R; Javadi, M; Mazloomi, S; Najibi, A; Niknahad, H; Ommati, MM; Rezaei, H; Sabouri, S; Yazdani, J, 2023) |
| "Cholestasis is a commonly occurring disorder induced by impaired bile flow, for which there is no effective treatment so far." | ( Chang, Y; Fan, F; Liu, X; Shi, Y; Xia, Y; Yan, S; Yu, P, 2023) |
| "Cholestasis is a disorder of bile secretion and excretion caused by a variety of etiologies." | ( Dai, S; Fu, K; Li, Y; Ma, C; Wang, C; Xue, X; Zhang, S; Zhang, Y; Zhou, H, 2023) |
| "Cholestasis is the main manifestation of cholestatic liver disease, which has a risk of progression to end-stage liver disease." | ( Han, J; Li, C; Liang, A; Liu, C; Liu, M; Liu, S; Meng, J; Pan, C; Qin, S; Tian, J; Wang, F; Wang, J; Wang, L; Yi, Y; Zhang, Y; Zhao, Y, 2024) |